Investigational Site Number 4022 — Boston, Massachusetts

Investigational Site Number 4022 is a clinical research site located in Boston, Massachusetts, United States 02115.

Crixeo Health Trust Score: 51/100 (POOR). This profile has not yet been claimed by the site owner.

Investigational Site Number 4022 has participated in 1 clinical trials.

Therapeutic areas: Primary Focal Segmental Glomerulosclerosis.

Sponsors: Genzyme, a Sanofi Company.

Sponsor Feasibility Report

Trust Score: 51/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Investigational Site Number 4022?

Investigational Site Number 4022 has a Crixeo Trust Score of 51/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Investigational Site Number 4022 conducted?

Investigational Site Number 4022 has 1 clinical trials on record. Their work covers Primary Focal Segmental Glomerulosclerosis.

Is Investigational Site Number 4022 accredited by Crixeo Health?

Investigational Site Number 4022 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Investigational Site Number 4022?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.